13F Holdings
中文EN

CANF Can-Fite BioPharma Ltd. Annual reports only

Pharmaceutical Preparations · NYSE · SEC CIK 1536196 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-39.9%
TTM net income YoY-24.7%
TTM EPS YoY45.0%
Revenue 3-yr CAGR-20.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,456.8%
Net margin-2,426.7%
FCF margin-2,210.1%
EBITDA margin-2,450.9%

Returns

ROE-178.2%
ROA-105.5%
ROIC (approx.)-2,329.0%
Asset turnover0.04x

Leverage & solvency

Liabilities / assets41.2%
Debt / equity0.00x
Current ratio3.46x
Interest coverage-35.04x

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$405,000$674,000$743,000$810,000$853,000
R&D expense$6.69M$5.76M$5.98M$7.76M$9.85M
SG&A expense$3.66M$3.05M$2.96M$3.14M$3.85M
Operating income-$9.95M-$8.13M-$8.20M-$10.10M-$12.84M
Interest expense$284,000$291,000$506,000-$222,000—
Pretax income-$9.83M-$7.88M-$7.63M-$10.17M-$12.62M
Net income-$9.83M-$7.88M-$7.63M-$10.17M-$12.62M
EBITDA-$9.93M-$8.12M-$8.18M-$10.08M-$12.83M
EPS (basic)-5.97-10.86-17.92-0.01-0.03
EPS (diluted)-5.97-10.86-17.92-0.01-0.03
Weighted avg. shares (diluted)1.65M725,309426,111815.75M553.08M
Banking
Net interest income———-$77,000$227,000
Balance sheet
Cash & equivalents$5.53M$4.83M$4.28M$2.98M$4.39M
Short-term investments$1,000$5,000$19,000$8,000$237,000
Current assets$9.44M$8.98M$9.91M$9.16M$20.07M
PP&E, net$5,000$27,000$29,000$42,000$47,000
Total assets$9.51M$9.12M$9.99M$9.28M$20.25M
Current liabilities$2.73M$2.05M$2.02M$2.50M$2.73M
Total liabilities$3.92M$3.68M$3.75M$4.81M$5.87M
Shareholders' equity$5.59M$5.44M$6.24M$4.47M$14.38M
Shares outstanding2.62M994,3941.36B815.75M815.75M
Cash flow statement
Operating cash flow-$8.95M-$7.64M-$8.44M-$10.80M-$9.86M
Capital expenditure$2,000$5,000$2,000$9,000$11,000
Free cash flow-$8.95M-$7.64M-$8.44M-$10.81M-$9.87M
Investing cash flow-$2,000$1.50M$498,000$9.50M-$14.51M
Financing cash flow$9.64M$6.71M$9.14M—$20.46M
Depreciation & amortization$24,000$7,000$15,000$14,000$14,000
Stock-based compensation$340,000$362,000$261,000$263,000$466,000
Dividends paid————$2.59M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.